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Background: Cardiovascular disease is the most frequent cause of death in Australia, with an associated cost
burden of 11% of Australian annual health expenditure of which 40% is for hospital admissions. We investigated
health outcomes and the components of hospital expenditure in the two years after an atherothrombotic disease
admission to a tertiary hospital in an Australian setting.
Methods: Using data linkage we analysed two years of hospitalisation data and death records of all men and
women aged 35–84 years with an admission to a Western Australian tertiary hospital for atherothrombotic disease
in 2007. Costs were identified by matching the Australian refined diagnostic related group on the admission
records to the published schedules of public and private hospital costs for the period of interest, and converted to
2013 Australian dollars.
Results: Of 6172 patients studied (74% coronary, 20% cerebrovascular, 6% peripheral), 783 (13%) died during
follow-up and 174 of these were in hospital case-fatalities at index. Thirty-two percent of patients (n = 1965)
accounted for 3172 readmissions to hospital with one in three having multiple hospitalisations. The hazard ratio of
atherothrombotic disease readmission was 1.45 (95% CI 1.27, 1.66) in those with more than one vascular territory
affected compared to those with only one territory affected after controlling for age, sex, comorbidity, admission
type, procedures, and episode length of stay. The total index plus 2-year admission cost for atherothrombotic
disease was calculated at $101 million; $71 million for index, and $30 million for readmissions.
Conclusions: Among patients hospitalised with atherothrombotic disease, the cost of related rehospitalisations
within 24 months is almost a third of the total. Much of the readmission costs fell within the first year. Whether
readmissions and cost associated with atherothrombotic disease can be lowered through secondary prevention
measures requires further investigation.
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Western AustraliaBackground
Cardiovascular disease (CVD) is the most frequent cause
of death in Australia, and commands more of the govern-
ment’s health expenditure than any other single disease.
Approximately 11% of Australian annual health expend-
iture is spent on CVD, of which 40% is for hospital admis-
sions [1]. Based on the latest health expenditure report
(2010–2011 financial year) this equates to $14 and $5.7* Correspondence: emily.atkins@uwa.edu.au
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unless otherwise stated.billion respectively [2]. Better understanding of the hospi-
talisation costs associated with first and recurrent CVD
events is central to evaluating the effectiveness of clinical
care and planning for disease prevention.
The majority of CVD is attributable to atherothrom-
botic disease (ATD). ATD describes the shared pathology
of atherosclerosis with superimposed thrombosis in is-
chaemic cerebrovascular disease (CeVD), coronary heart
disease (CHD), and peripheral arterial disease (PAD); the
combined determinants of CVD [3]. Atherothrombotic
events in the cerebral and coronary arteries are lifetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics at index admission to
tertiary hospital in 2007
Characteristics n = 6172
Age, mean (SD) 65.3952 (11.82)
Age group, n (%)
35-44 years 321 (5.20)
45-54 years 912 (14.78)
55-64 years 1499 (24.29)
65-74 years 1758 (28.48)
75-84 years 1682 (27.25)
Male, n (%) 4036 (65.39)
Episode length of stay, median (min, max) 3 (1, 357)
Accessibility and remoteness, n (%) n = 5902
Major city 4678 (79.26)
Inner regional 677 (11.47)
Outer regional 333 (5.64)
Remote 137 (2.32)
Very remote 77 (1.30)
Australian socio-economic indices for area – Disadvantage, n (%)
n = 5902




Least Q5 980 (16.60)
Atherothrombotic disease subtype at index admission
Coronary heart disease, n (%) 4571 (74.06)
Cerebrovascular disease, n (%) 1242 (20.12)
Peripheral arterial disease, n (%) 359 (5.8)
History of polyvascular disease at index admission 768 (12.44)
Comorbidities at index admission
Hypertension, n (%) 4009 (64.95)
Diabetes, n (%) 1683 (27.27)
Chronic kidney disease, n (%) 758 (12.28)
Atrial fibrillation, n (%) 1005 (16.28)
Heart failure, n (%) 862 (13.97)
Chronic lung disease, n (%) 764 (12.38)
Cancer, n (%) 1636 (26.51)
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teries are predominately limb threatening. Such events
require urgent hospitalisation and intervention to pre-
vent death and/or loss of a limb. Furthermore, second-
ary prevention is a vital part of ATD management as
those who have experienced one atherothrombotic
event are at high absolute risk of further manifestations of
the disease [4-6]. But it is well understood that not all
those who could benefit from secondary prevention
pharmacotherapy receive it [7]. Work by Ademi et al. sug-
gests that Western Australians are under-treated com-
pared with the other Australian states [8]. Furthermore,
analysis of pharmacy data by Gunnell et al. suggests that
a large proportion of Western Australian patients with
coronary heart disease are not filling scripts for all rec-
ommended therapeutic types in 28 days [9].
The two year medical costs of ATD have been modelled
for eight European countries, [10] and 12- and 18-month
costs have been modelled in another two [11,12]. How-
ever, the two year hospital costs and outcomes of a cohort
of patients hospitalised with ATD has yet to be described
in an Australian context, particularly in terms of time
from discharge. Our objective is to determine the health
outcomes and estimate hospital costs for ATD in the two




The study sample comprised all Western Australian
residents aged 35–84 years admitted to a tertiary public
hospital in Perth during 2007 with a primary diagnosis of
ATD selected using methods previously published [13]. In
Western Australia (WA) the tertiary hospitals provide
patients with acute and elective arterial interventions such
as coronary angiograms and invasive vascular procedures,
these were not available at outer metropolitan and rural
public hospitals until quite recently, and as such tertiary
hospitals were the only public hospitals that provided
these services in the study period. At discharge, a letter is
sent to the patient’s general practitioner (GP), if they have
one, and a copy is given to the patient. The hospital doctor
also has the option of seeing the patient in an outpatient
clinic some time after discharge, especially if the patient
does not have a GP. These services are not captured by
the linked administrative data and are not included in this
analysis.
The first ATD admission to a tertiary hospital in 2007
was identified and considered the index admission (this
could be incident or recurrent ATD). Major comorbidi-
ties for ATD were also identified [13]. A history of ATD
or comorbidity was recorded where so coded in any one
of 21 diagnostic fields for any hospitalisation, including
the index presentation, during the preceding 15 years[14]. Cardiovascular cause of death was defined by ICD
10 - AM code from I00 to I99.
Data source
The data was extracted from two of the state’s adminis-
trative databases, the Hospital Morbidity Data Collection
(HMDC) and Death Registrations. The HMDC covers
all admissions to any public or private hospital in WA,
while death registrations include those deaths registered
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age System at the Department of Health [15]. Data linkage
is performed using probabilistic matching with clerical re-
view [16]. The estimated proportion of invalid and missed
links was 0.11% in 1996 [16] and linkage quality is ex-
pected to remain at this level for links between hospital
and death records.
An episode of care refers to the period from a person’s
first admission to the hospital system until they leave the
hospital system. This may be an admission and discharge
from the same hospital, or a contiguous set of transfers
among hospitals. Rehospitalisation or readmission refers
to episodes of care occurring after the index event.
Rehospitalisation and death data were available for two
years after the index event.
Ethics approval was obtained from the Human Research
Ethics Committees at the WA Department of Health and
The University of Western Australia.Costs
Costs were identified by matching the Australian refined
diagnostic related group (AR-DRG) on the HMDC ad-
mission records to the published schedules of public
and private hospital costs for the years from 2007 to
2009. We used AR-DRG version 5.1 public and private
costs for admissions in 2007 and 2008, [17,18] and the
AR-DRG version 6.0 estimated public cost weights for
admissions in 2009 [19]. No private costs have been pub-
lished for 2009. Costs were then converted to constant
2013 Australian dollars using health index deflators [2].
Individual level costs for ATD episodes of care (defined
as an ATD code in the primary diagnosis field at least
once during the episode) were calculated on the index ad-
mission, and summed for readmissions up to 24 months
following the index admission.Table 2 Number of recurrent ATD hospital admissions in two
stay per admission, days, within age group
No of recurrent admissions 0
35-44 years N (%) 242 (75.4)
Mean length of stay -
45-54 years N (%) 616 (67.5)
Mean length of stay -
55-64 years N (%) 1021 (68.1)
Mean length of stay -
65-74 years N (%) 1168 (66.4)
Mean length of stay -
75-84 years N (%) 1160 (69.0)
Mean length of stay -
Total (%) 4207 (68.2)Accessibility and remoteness and socio-economic
disadvantage
The linked dataset included an Accessibility/Remoteness
Index for Australia (ARIA+) and Socio-Economic Indices
For Area (SEIFA) disadvantage score for each admission.
ARIA + is based on distance by road to reach service
centres [20]. Residence at the time of hospitalisation
was categorised as: major city, inner regional, outer re-
gional, remote, or very remote. This was further grouped
as metropolitan (major city) and rural (inner regional,
outer regional, remote, and very remote). SEIFA disadvan-
tage scores are an area level measure based on census data
relating to income, education, unemployment and motor
vehicle ownership [21]. These scores are ranked and
pooled into deciles, and were grouped into quintiles for
this analysis. SEIFA disadvantage and ARIA + indices were
missing for 270 (4%) patients.
Statistical methods
Mean costs per individual for the index admission and
for subsequent readmissions to 90 days, from 90 days to
12 months, and 12 to 24 months after index were calcu-
lated by 10-year age groups (35–44 years, 45–54 years,
55–64 years, 65–74 years, and 75–84 years at index ad-
mission), vascular territory, SEIFA disadvantage quintile,
and ARIA + category of the index admission. Mean costs
are presented as they reflect the population level costs.
Chi-square test was used to compare the proportion of
deaths in each age group.
Analysis of variance and t-tests were used to compare
mean costs by age, sex, metropolitan or rural residence
and socioeconomic disadvantage quintile. Cox regression
was used to investigate factors associated with time to
first ATD readmission within 2 years (and censored if died
within 2 years). Age group, sex, rural or metropolitan resi-
dence, SEIFA disadvantage quintile, emergency or electiveyears from index admission, n (%), and mean length of
1 2 3+ Total
49 (15.3) 21 (6.5) 9 (2.8) 321
7.2 4.2 4.1 5.3
205 (22.5) 59 (6.5) 32 (3.5) 912
7.7 3.6 2.8 5.3
311 (20.8) 100 (6.7) 67 (4.5) 1499
4.0 3.8 4.8 4.2
399 (22.7) 117 (6.7) 74 (4.2) 1758
4.7 5.8 4.0 4.8
355 (21.1) 96 (5.7) 71 (4.2) 1682
8.8 7.4 4.6 7.0
1319 (21.4) 393 (6.4) 253 (4.1) 6172
Figure 1 Two year readmission characteristics of patients by vascular territory of index admission. Branches may not add to 100% due to
rounding *some patients have more than one readmission.
Table 3 Cox hazard ratios for time to next ATD episode
of care within 2 years by index admission vascular
territory and index admission type (censored at death or
2 years)
Emergency Elective p-value
Recurrent PAD 2.61 (1.66, 4.10) 1.36 (0.99, 1.86) 0.0192
Incident PAD 2.29 (1.63, 3.22) 1.09 (0.81, 1.46) 0.0011
Recurrent CeVD 0.56 (0.40, 0.78) 0.62 (0.30, 1.26) 0.7973
Incident CeVD 0.42 (0.34, 0.51) 0.51 (0.29, 0.90) 0.4981
Recurrent CHD 1.29 (1.14, 1.46) 0.92 (0.77, 1.10) 0.0020
Incident CHD 1.00 1.00 -
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CeVD, or CHD), polyvascular disease (more than one ter-
ritory affected), comorbidity history, and length of stay at
the index admission were included in the base Cox model.
Forward selection with significance level for entry set to
0.01 was used to check for interactions with age group,
sex, polyvascular disease and index vascular territory. Stat-
istical analysis was performed using SAS 9.4.
Results
Index admission
The sample comprised 6172 patients, the characteristics
of which are presented in Table 1. Approximately two
thirds were male, 79% were metropolitan residents and
21% in the most disadvantaged quintile. Coronary heart
disease was the most common index diagnosis (n = 4571;
74%) and hypertension the most common comorbidity(n = 4009; 65%). Twenty-nine percent of patients had an
ATD-related procedure at index, of these two-thirds had
coronary stent procedures, 17% peripheral procedures,
and 15% coronary artery bypass grafts.
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There were 783 (13%) deaths in the two years (including
those occurring at the index event) and of these 439 had
a cardiovascular cause of death code. Most deaths oc-
curred in the first twelve months after the index event
(n = 557; 71%). Of these, 174 (2.8% of total studied) were
in-hospital case-fatalities at the time of the index event
and another 85 out-of-hospital fatalities occurred in the
28 days following their index admission. The oldest age
group experienced the greatest proportion of deaths witha
b
Figure 2 Mean ATD admission costs per person at index (2007), 90 d
age group. Costs are 2013 Australian dollars.much smaller proportions in the younger age groups
(35–44 years, n = 15, 1.92%; 45–54 years, n = 56, 7.15%;
55–64 years, n = 95, 12.13%; 65–74 years, n = 190, 24.27%;
and 75–84 years, n = 427, 54.53%; p < 0.0001).
Readmissions
Thirty-two percent (1965) of patients had at least one
ATD readmission in the 2 years after the index admis-
sion and 1077 of those patients had a readmission in the
first 90 days after the index admission. Fifty seven perays, 1 year, and 2 years by sex (Panel a male and b female) and
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shows the distribution of ATD readmissions and mean
length of stay per admission by age group and overall.
Figure 1 shows the pattern of readmissions over 2 years
by type of index admission. Almost half of the patients
with PAD were readmitted, mostly as elective cases.
Whereas, a third of patients with CHD and one in seven
with CeVD were readmitted and more so as emergency
presentations. Readmissions involving another vascular
territory were highest for stroke (39%), followed by PAD
(20%) and CHD (7%). The proportions readmitted by
index vascular territory was similar for each 10-year age
group.
Factors associated with time to ATD readmission
Having ATD in more than one vascular territory at the
index admission was highly significant, with the risk of
ATD readmission approximately 1.5 times higher in those
with polyvascular disease compared to those with only
one vascular territory affected controlling for age, sex, co-
morbidity, admission type, procedures, and episode length
of stay (HR 1.45; 95% CI 1.27, 1.66). Rural or metropolitan
residence and SEIFA disadvantage quintile were not in-
cluded in the final model as they were non-significant and
missing values were restricting the study sample included
in the analysis. The risk of readmission was 2.3 to 2.6
times higher for incident or recurrent PAD than incident
CHD for emergency index admissions, but not for elective
index admissions (Table 3). The risk of readmission was
1.3 times higher for recurrent CHD than incident CHD
for emergency, but not elective. The risk of readmission
was lower for incident and recurrent CeVD than incident
CHD, but not statistically significant for elective recurrent
CeVD.
In a Cox model with age group alone, the risk of re-
admission was lowest in the 35–44 years age group and all
other age groups had similar risk (HR = 1.402 for 45–54
years, HR = 1.370 for 55–64 years, HR = 1.481 for 65–74
years, and HR = 1.460 for 75–84 years; all vs 35–44 years).
However, in the fully adjusted model (polyvascular disease,
index territory, sex, comorbidity, admission type, proce-
dures, and episode length of stay), the risk of readmissionTable 4 Mean and standard deviation of atherothrombotic di




Coronary heart disease, mean (SD) ATD admission
costs
$9602 ($12249)
Cerebrovascular disease, mean (SD) ATD admission
costs
$18416 ($19228)
Peripheral vascular disease, mean (SD) ATD
admission costs
$11652 ($15672)
†Cerebrovascular disease significantly different from coronary heart disease and petends to increase with age (HR = 1.290 for 45–54 years,
HR = 1.265 for 55–64 years, HR = 1.348 for 65–74 years,
and HR = 1.401 for 75–84 years; all vs 35–44 years).
Costs
The total index plus 2-year admission cost for ATD was
calculated at $101 million; $71 million for index (6172
episodes of care), and $30 million for readmissions,
comprising $14 million in the 90 days after the index ad-
mission, $9 million from 90 days to 12 months, and $7
million from 12 to 24 months. Hospital admission costs
were highly skewed with many patients not contributing
readmission costs and a few patients contributing very
high costs.
Figure 2 shows the mean ATD admission costs for
men and women at each time point across five age
groups. At index the mean cost of admission was not
significantly higher for men ($11736, SD $14921) com-
pared with women ($11039, SD $13846; p = 0.0673). How-
ever, readmission costs for ATD by sex at 90 days,
12 months were significantly higher for men, but not at
24 months follow-up (p < 0.0001; p = 0.0449; and p = 0.8586
respectively). There were no statistically significant dif-
ferences in mean costs between age groups at each time
point within males and females.
Index CeVD admissions had the highest mean cost
($18416, SD $19228), whilst patients with a PAD index
admission had the highest mean readmission costs at 12
and 24 months (Table 4).
Emergency index admissions had the highest mean
cost (Table 5). Of the readmission costs, the highest
mean was for elective admissions within 90 days from
index admission. Readmission costs decreased over time.
Rural residents, those in the inner and outer regional,
remote and very remote ARIA + categories, had higher
mean costs for the index tertiary hospital admission
compared to major city residents ($13030 vs. $11088;
p = 0.0001). Rural residents have a slightly longer, though
not statistically significant, episode length of stay on the
index admission. Readmission costs at each follow-up
point were also slightly higher for rural residents, but the
difference did not reach statistical significance.sease admission costs per person at index admission and
months after index by vascular territory of index
At 90 days after
index admission‡
90 days to 12 months
after index admission‡
12 to 24 months after
index admission‡
$2641 ($7866) $1516 ($6291) $1073 ($4836)
$648 ($3702) $875 ($4885) $726 ($5396)
$4576 ($11299) $3746 ($10426) $3172 ($15494)
ripheral arterial disease. ‡Significant differences between all vascular territories.
Table 5 Mean and standard deviation of atherothrombotic disease admission costs by admission type per person
using AR-DRGs adjusted to 2013 $AUD, rounded to whole dollars (n = 6172)
Index admission At 90 days from
index admission
90 days to 12 months
from index admission
12 to 24 months from
index admission
Emergency admissions, mean (SD) ATD admission costs $12957 ($15152) $858 ($4891) $830 ($4642) $703 ($4188)
Elective admissions, mean (SD) ATD admission costs $8595 ($12422) $1566 ($6041) $725 ($4408) $488 ($4701)
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the highest costs at index, 90 days, and 12 months
(Table 6). At index and 24 months there were no statisti-
cally significant differences in mean costs between
quintiles.
Discussion
Of those admitted to a Perth tertiary hospital for ATD
in 2007, 13% died and 32% experienced a readmission
within 24 months. The 2-year cost to the health system,
including index admission, was $101 million (2013
Australian dollars). Readmission costs for ATD in
24 months following an index admission were approxi-
mately 42% of the total, with more than three-quarters
of these costs falling in the first 12 months after the
index event.
A much greater proportion of those in the youngest
age group had no readmissions, but there were remark-
able similarities in the four older age groups and this
cannot be explained by reduced follow-up in older age
groups due to more deaths, as the estimated risks of
readmission from the unadjusted Cox model showed a
similar age pattern, reflecting the age-specific risks re-
ported by Briffa et al. [22]. In the fully adjusted Cox
model however there appeared to be an increasing risk
of readmission with increasing age.
Those with PAD experienced a high proportion of
readmissions. Almost half of the PAD group experienced
at least one readmission, and 80% of their readmissions
were for PAD. PAD-related hospital admissions are
usually for advanced disease requiring costly vascular
procedures. Those with PAD are known to be pre-
scribed fewer cardio-protective medications than their
counterparts who have experienced CeVD or CHD [8].
Improved use of secondary prevention drugs has theTable 6 Mean and standard deviation of atherothrombotic di
using AR-DRGs adjusted to 2013 $AUD, rounded to whole do
Australian socio-economic indices for area –
Disadvantage, mean (SD) ATD admission costs
Index admission At
in
Most disadvantaged Q1 $12118 ($15332) $2
Q2 $11543 ($14281) $2
Q3 $11035 ($13825) $2
Q4 $11417 ($14287) $1
Least disadvantaged Q5 $11322 ($15512) $2
Q = quintile †Significant differences between Q1 and Q5, and Q1 and Q4. ‡Significapotential to reduce atherothrombotic change and delay or
prevent hospital admissions for vascular procedures [23].
The international REACH registry reported that in
three years of follow-up 28.4% of those with existing
ATD experienced a vascular event or readmission after
adjustment for age and sex, with those with CeVD ex-
periencing the lowest readmission rates and PAD the
highest [24]. We observed a similar pattern of lower
readmissions in CeVD and higher in PAD, but our study
population experienced a greater proportion of readmis-
sions. This is likely due to the selection of our study
sample based on admission proximity, whereas the inter-
national REACH registry recruited from general practice.
The Oxford Vascular Study did have an acute ATD event
as the baseline but the outcome of interest included acute
events only, with 16 per cent having at least one recurrent
acute event [25]. This population experienced a much
higher proportion of CeVD (45%) and PAD (9%), and a
lower proportion of CHD (42%). The large difference in
CeVD may be attributed to the inclusion of those aged
85 years and older. The effects of polyvascular ATD and
the index vascular territory on the risk of readmission for
ATD are not unexpected. It likely reflects the use of vascu-
lar interventions and the complexity/severity of disease
involving multiple territories.
The ATD hospital admission costs at 12 months for
CHD, CeVD, and PAD are slightly higher than the mean
hospital costs published by Ademi et al. in their analysis of
the Australian REACH registry data in general practice pa-
tients [26]. Only 12% of their study sample experienced a
hospital admission in the one year of follow-up and almost
11% of REACH participants had no prior ATD hospitalisa-
tion, suggesting a more clinically stable population.
A European analysis by Levy and colleagues also indi-
cated that the vast majority of costs are incurred in thesease admission costs by admission type per person
llars (n = 5902)
90 days from
dex admission†
90 days to 12 months
from index admission†‡
12 to 24 months from
index admission
855 ($9425) $1934 ($7442) $1077 ($3934)
282 ($7056) $1587 ($6991) $1140 ($5539)
339 ($6974) $1578 ($6545) $1279 ($8550)
991 ($6052) $1254 ($5120) $1303 ($6694)
192 ($7843) $901 ($3888) $827 ($4703)
nt differences between Q2 and Q5, and Q3 and Q5.
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the different countries [10]. The proportion of follow-up
costs to acute costs for stroke in Europe ranged from
22% in Portugal to over 300% in France and Switzerland,
though this included rehabilitation, which was not in-
cluded in our study. For myocardial infarction it ranged
between 33% in Portugal up to 114% in Austria.
The current study reports the costs associated with
hospital readmissions for ATD in Perth Tertiary Hospitals.
AR-DRGs have enabled measurement of the cost of ATD
in such a large unselected sample. Indeed, a strength of
the study is the bottom-up approach to costing by apply-
ing the individual AR-DRG costs to each admission in the
dataset, based on the AR-DRG assigned in the HMDC.
This means that the cost will best reflect the patient’s
hospital admission and care costs. However, the costs
assigned to AR-DRGs are based on an average patient
across Australia and therefore may not reflect the pre-
cise costs incurred as a result of their admission.
Conclusions
In conclusion, among patients hospitalised with ATD
the total 2-year cost to the health system at $101 million
is substantial. The costs of ATD-related rehospitalisation
within 90 days of the index admission are also sizable,
across age and sex categories, and readmission costs
within 24 months is 42% of the baseline admission costs.
With 3172 readmissions, and well-known prevention
treatment gap, there is a need to further investigate the
cost-effectiveness of secondary prevention pharmacother-
apy as a potential means for reducing readmissions and
costs, in this setting.
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